Letter to the Editor for the Article“efficacy and Safety of Neoadjuvant Sintilimab in Combination with FLOT Chemotherapy in Patients with HER2-negative Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: an Investigator-Initiated, Single-Arm, Open-Label, Phase II Study”